Friday, July 10, 2026
🇺🇸 FDA

Drug profile · INN

axatilimab

axatilimab is a macrophage colony stimulating factor receptor inhibitor.

NMPA: clinical trials
Patents linked 0
Pipeline programs 9
News articles 1
Drug details — axatilimab
Class
—
Route
—
Patents
0
Programs
9
Data quality
0.70
← All drugs Search patents Pipeline programs Drug news hub Event calendar

Quick answer

axatilimab is a macrophage colony stimulating factor receptor inhibitor.

Key facts

INN axatilimab
Mechanism Macrophage colony stimulating factor receptor inhibitor
Target Macrophage colony-stimulating factor 1 receptor

Mechanism of action

Macrophage colony stimulating factor receptor inhibitor

Primary target: Macrophage colony-stimulating factor 1 receptor

Approval history

Authority Status Date
NMPA clinical trials —

Recent coverage

View all news
Syndax pipeline update: Revuforj and Niktimvo catalysts to watch
Critical impact NewsJun 8, 2026

Syndax pipeline update: Revuforj and Niktimvo catalysts to watch

FDA · 8 min

This Syndax pharmaceuticals news plan focuses on the company’s approved assets, revumenib and axatilimab, and the next clinical catalysts that matter to analysts. It is built to support competitive benchmarking, FDA context, and investment-useful follow-up.

Dr. Sarah Mitchell

Pipeline programs

Search pipeline
  1. Axatilimab (INCA034176) Phase 3 · Incyte · Chronic Graft-Versus-Host Disease
  2. INCA34176-357 Phase 3 · Incyte · chronic graft-versus-host disease
  3. AXATILIMAB Phase 2 · Syndax Pharmaceuticals · Chronic graft versus host disease (cGVHD)
  4. AXATILIMAB, Placebo Phase 2 · Syndax Pharmaceuticals · Idiopathic pulmonary fibrosis
  5. Axatilimab Phase 2 · Syndax Pharmaceuticals · Idiopathic Pulmonary Fibrosis
  6. Axatilimab Phase 2 · Syndax Pharmaceuticals · Chronic Graft-versus-host-disease
  7. Axatilimab (INCA034176) Phase 2 · Incyte · Chronic Graft-Versus-Host Disease
  8. INCA34176-254 Phase 2 · Incyte · chronic graft-versus-host disease

Related & competitor drugs

Browse all drugs
  1. sunitinib malate Vascular endothelial growth factor receptor inhibitor
  2. axatilimab-csfr Macrophage colony stimulating factor receptor inhibitor
  3. pexidartinib hydrochloride Tyrosine-protein kinase receptor FLT3 inhibitor
  4. pexidartinib Antineoplastic and immunomodulating agents (L01)
  5. quizartinib Antineoplastic and immunomodulating agents (L01)
  6. sunitinib Antineoplastic and immunomodulating agents (L01)

Frequently asked questions

What is axatilimab?

axatilimab is a macrophage colony stimulating factor receptor inhibitor.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.